Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carboxymethylcellulose Based Lubricant Eye · 1 trial · 1 indication
The Ocular Surface Disease Index© Questionnaire is a 12-item survey assessing the overall severity of dry eye disease per patient. Each question is rated on a 5-point scale ranging from 0=none of the time to 4=all of the time for a total possible score of 0=No disease to 100=Maximum severity of disease. A negative change from baseline indicates improvement.
| Arm | Type | Description |
|---|---|---|
| Carboxymethylcellulose Based Eye Drop Formulation A | EXPERIMENTAL | Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Eye Drop Formulation B | EXPERIMENTAL | Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Preservative-Free Lubricant Eye Drops | ACTIVE_COMPARATOR | Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Lubricant Eye Drops | ACTIVE_COMPARATOR | Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
| Name | Type | Description |
|---|---|---|
| Carboxymethylcellulose Based Eye Drop Formulation A | DRUG | Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Eye Drop Formulation B | DRUG | Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops | DRUG | Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days. |
| Carboxymethylcellulose Based Lubricant Eye Drops | DRUG | Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days. |
Inclusion Criteria: * Dry eyes * Current use of eye drops for dry eye at least twice daily, on average for at least 3 months Exclusion Criteria: * Cataract, laser-assisted in situ keratomileusis (LASIK), or photorefractive keratectomy (PRK) surgery in the last 12 months * Need to wear contact len...
Top 20 of 34 competitors
Carboxymethylcellulose Based Lubricant Eye is used for dry eye syndromes. It is an ophthalmology product being developed as a small molecule. The drug is intended to provide lubrication for the eye in patients with dry eye disease.
Carboxymethylcellulose Based Lubricant Eye is being developed by AbbVie Inc., which trades under the ticker ABBV. The company is conducting clinical research on this lubricant eye drop formulation for the treatment of dry eye syndromes.
Carboxymethylcellulose Based Lubricant Eye is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under clinical investigation for dry eye syndromes.
Carboxymethylcellulose Based Lubricant Eye has one completed Phase 3 clinical trial, NCT01459588, titled "Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease." The trial enrolled 315 participants in the United States and included adults aged 18 years and older.
Yes, the Phase 3 clinical trial for Carboxymethylcellulose Based Lubricant Eye was randomized, double-blind, and active-controlled. The study compared the eye drop formulation against an active control in patients with dry eye disease, and it enrolled 315 participants.